Humacyte, a biotech company, will hold a virtual key opinion leader event on April 28, 2026, to discuss its Acellular Tissue Engineered Vessel (ATEV) for arteriovenous (AV) access in hemodialysis patients with End-Stage Renal Disease (ESRD). The ATEV offers an alternative to traditional AV fistulas, which often take weeks or months to mature and sometimes fail. The event will feature expert discussions and updates on ongoing Phase 3 trials, with interim results expected soon. This technology aims to improve treatment options for hemodialysis patients and is currently under FDA investigation for uses beyond vascular trauma.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
